434 related articles for article (PubMed ID: 33948592)
1. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
bioRxiv; 2021 Apr; ():. PubMed ID: 33948592
[TBL] [Abstract][Full Text] [Related]
2. Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies.
Jette CA; Cohen AA; Gnanapragasam PNP; Muecksch F; Lee YE; Huey-Tubman KE; Schmidt F; Hatziioannou T; Bieniasz PD; Nussenzweig MC; West AP; Keeffe JR; Bjorkman PJ; Barnes CO
Cell Rep; 2021 Sep; 36(13):109760. PubMed ID: 34534459
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity.
Jensen JL; Sankhala RS; Dussupt V; Bai H; Hajduczki A; Lal KG; Chang WC; Martinez EJ; Peterson CE; Golub ES; Rees PA; Mendez-Rivera L; Zemil M; Kavusak E; Mayer SV; Wieczorek L; Kannan S; Doranz BJ; Davidson E; Yang ES; Zhang Y; Chen M; Choe M; Wang L; Gromowski GD; Koup RA; Michael NL; Polonis VR; Rolland M; Modjarrad K; Krebs SJ; Joyce MG
J Virol; 2023 Jul; 97(7):e0159622. PubMed ID: 37395646
[TBL] [Abstract][Full Text] [Related]
4. Broad Sarbecovirus Neutralizing Antibodies Obtained by Computational Design and Synthetic Library Screening.
Yang X; Duan H; Liu X; Zhang X; Pan S; Zhang F; Gao P; Liu B; Yang J; Chi X; Yang W
J Virol; 2023 Jul; 97(7):e0061023. PubMed ID: 37367229
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ
Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711
[TBL] [Abstract][Full Text] [Related]
6. Delineating the functional activity of antibodies with cross-reactivity to SARS-CoV-2, SARS-CoV-1 and related sarbecoviruses.
Ruiz F; Foreman W; Lilly M; Baharani VA; Depierreux DM; Chohan V; Taylor AL; Guenthoer J; Ralph D; Matsen FA; Chu HY; Bieniasz PD; Côté M; Starr TN; Overbaugh J
bioRxiv; 2024 Apr; ():. PubMed ID: 38712126
[TBL] [Abstract][Full Text] [Related]
7. Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability.
Burnett DL; Jackson KJL; Langley DB; Aggrawal A; Stella AO; Johansen MD; Balachandran H; Lenthall H; Rouet R; Walker G; Saunders BM; Singh M; Li H; Henry JY; Jackson J; Stewart AG; Witthauer F; Spence MA; Hansbro NG; Jackson C; Schofield P; Milthorpe C; Martinello M; Schulz SR; Roth E; Kelleher A; Emery S; Britton WJ; Rawlinson WD; Karl R; Schäfer S; Winkler TH; Brink R; Bull RA; Hansbro PM; Jäck HM; Turville S; Christ D; Goodnow CC
Immunity; 2021 Dec; 54(12):2908-2921.e6. PubMed ID: 34788600
[TBL] [Abstract][Full Text] [Related]
8. Defining a de novo non-RBM antibody as RBD-8 and its synergistic rescue of immune-evaded antibodies to neutralize Omicron SARS-CoV-2.
Rao X; Zhao R; Tong Z; Guo S; Peng W; Liu K; Li S; Wu L; Tong J; Chai Y; Han P; Wang F; Jia P; Li Z; Zhao X; Li D; Zhang R; Zhang X; Zou W; Li W; Wang Q; Gao GF; Wu Y; Dai L; Gao F
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2314193120. PubMed ID: 38109549
[TBL] [Abstract][Full Text] [Related]
9. Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.
Barnes CO; Jette CA; Abernathy ME; Dam KA; Esswein SR; Gristick HB; Malyutin AG; Sharaf NG; Huey-Tubman KE; Lee YE; Robbiani DF; Nussenzweig MC; West AP; Bjorkman PJ
bioRxiv; 2020 Aug; ():. PubMed ID: 32869026
[TBL] [Abstract][Full Text] [Related]
10. Structural basis for the broad and potent cross-reactivity of an N501Y-centric antibody against sarbecoviruses.
Jeong BS; Jeon JY; Lai CJ; Yun HY; Jung JU; Oh BH
Front Immunol; 2022; 13():1049867. PubMed ID: 36466915
[TBL] [Abstract][Full Text] [Related]
11. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
12. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Antibody Effectiveness Is Influenced by Non-Epitope Mutation/Binding-Induced Denaturation of the Epitope 3D Architecture.
Malisheni MM; Bates M; Rizvanov AA; MacAry PA
Pathogens; 2022 Nov; 11(12):. PubMed ID: 36558771
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
15. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
[TBL] [Abstract][Full Text] [Related]
16. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
18. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
Elife; 2022 Aug; 11():. PubMed ID: 36004719
[TBL] [Abstract][Full Text] [Related]
19. Epitope Profiling Reveals the Critical Antigenic Determinants in SARS-CoV-2 RBD-Based Antigen.
Jiang M; Zhang G; Liu H; Ding P; Liu Y; Tian Y; Wang Y; Wang A
Front Immunol; 2021; 12():707977. PubMed ID: 34621266
[TBL] [Abstract][Full Text] [Related]
20. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
